HLA DP DQ DR antibody | WR18

100% Secure


Mouse anti Human HLA DP DQ DR:FITC

Mouse anti Human HLA DP DQ DR

Mouse anti Human HLA DP DQ DR:RPE

Product Type
Monoclonal Antibody
Clone
WR18
Isotype
IgG2a
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
MCA477F F 0.1 mg
MCA477 F FN* P* 0.2 mg
MCA477PE F 100 Tests
Mouse anti Human HLA DP DQ DR antibody, clone WR18 reacts with a monomorphic determinant common to DP, DQ and DR beta chains, which are expressed by antigen presenting cells, B cells, monocytes and activated T lymphocytes.

The major histocompatibility complex (MHC) is a cluster of genes that are important in the immune response to infections. In humans, this complex is referred to as the human leukocyte antigen (HLA) region. There are 3 major MHC class II proteins encoded by the HLA which are HLA DP, HLA DQ and HLA DR.

Product Details

Target Species
Human
Product Form
Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
Product Form
Purified IgG - liquid
Product Form
Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
Reconstitution
Reconstitute with 1 ml distilled water
Preparation
Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide
Preservative Stabilisers
0.09%Sodium Azide
0.1%Bovine Serum Albumin
Immunogen
Human HLA Class II (DP, DQ, DR).
Approx. Protein Concentrations
IgG concentration 0.1 mg/ml
Approx. Protein Concentrations
IgG concentration 1 mg/ml
Fusion Partners
Spleen cells from immunised BALB/c mice were fused with cells from NS0 mouse myeloma cell line.

Storage Information

Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.

DO NOT FREEZE.

This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.
Shelf Life
12 months from date of reconstitution.

More Information

Regulatory
For research purposes only

Applications of HLA DP DQ DR antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry Neat 1/10
Flow Cytometry 1/50 1/200
Functional Assays 1
Immunohistology - Paraffin 2
Flow Cytometry Neat
  1. 1 This product contains sodium azide, removal by dialysis is recommended prior to use in functional assays. Bio-Rad recommend the use of EQU003 for this purpose.
  2. 2This product requires antigen retrieval using heat treatment prior to staining of paraffin sections.Sodium citrate buffer pH 6.0 is recommended for this purpose.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells in 100ul.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood
Histology Positive Control Tissue
Tonsil

Secondary Antibodies Available

Description Product Code Pack Size Applications List Price Quantity
Human anti Mouse IgG2a:FITC HCA037F 0.1 mg F
Human anti Mouse IgG2a:HRP HCA037P 0.1 mg E
Goat anti Mouse IgG (H/L):Alk. Phos. (Multi Species Adsorbed) STAR117A 0.5 mg E WB
Goat anti Mouse IgG (H/L):DyLight®488 (Multi Species Adsorbed) STAR117D488GA 0.1 mg F IF
Goat anti Mouse IgG (H/L):DyLight®549 (Multi Species Adsorbed) STAR117D549GA 0.1 mg F IF WB
Goat anti Mouse IgG (H/L):DyLight®649 (Multi Species Adsorbed) STAR117D649GA 0.1 mg F IF
Goat anti Mouse IgG (H/L):DyLight®680 (Multi Species Adsorbed) STAR117D680GA 0.1 mg F WB
Goat anti Mouse IgG (H/L):DyLight®800 (Multi Species Adsorbed) STAR117D800GA 0.1 mg F IF WB
Goat anti Mouse IgG (H/L):FITC (Multi Species Adsorbed) STAR117F 0.5 mg F
Goat anti Mouse IgG (H/L):HRP (Multi Species Adsorbed) STAR117P 0.5 mg E WB
Goat anti Mouse IgG (Fc):FITC STAR120F 1 mg C F
Goat anti Mouse IgG (Fc):HRP STAR120P 1 mg E WB
Rabbit F(ab')2 anti Mouse IgG:RPE STAR12A 1 ml F
Rabbit F(ab')2 anti Mouse IgG:HRP (Human Adsorbed) STAR13B 1 mg C E P RE WB
Goat anti Mouse IgG:FITC (Rat Adsorbed) STAR70 0.5 mg F
Goat anti Mouse IgG:RPE (Rat Adsorbed) STAR76 1 ml F
Goat anti Mouse IgG:HRP (Rat Adsorbed) STAR77 0.5 mg C E P
Goat anti Mouse IgG/A/M:Alk. Phos. STAR87A 1 mg C E WB
Goat anti Mouse IgG/A/M:HRP (Human Adsorbed) STAR87P 1 mg E
Rabbit F(ab')2 anti Mouse IgG:Dylight®800 STAR8D800GA 0.1 mg F IF WB
Rabbit F(ab')2 anti Mouse IgG:FITC STAR9B 1 mg F

Negative Isotype Controls Available

Description Product Code Pack Size Applications List Price Quantity
Mouse IgG2a Negative Control:FITC MCA929F 100 Tests F
Mouse IgG2a Negative Control MCA929 100 Tests F
Mouse IgG2a Negative Control:RPE MCA929PE 100 Tests F

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
Human Seroblock BUF070A 50 Test F
Human Seroblock BUF070B 200 Test F
Human Seroblock BUF070A 50 Test F
Human Seroblock BUF070B 200 Test F

Application Based External Images

Flow Cytometry

Functional Assays

Immunohistology - Paraffin

Product Specific References

References for HLA DP DQ DR antibody

  1. Moore, K. et al. (1987) Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy.
    J. Pathol. 152:13-21.
  2. Kissner, T.L. et al. (2011) Activation of MyD88 Signaling upon Staphylococcal Enterotoxin Binding to MHC Class II Molecules.
    PLoS One. 6: e15985.
  3. Chia, J.S. et al. (2001) Human T-cell responses to the glucosyltransferases of Streptococcus mutans.
    Clin Diagn Lab Immunol. 8: 441-5.
  4. Chang, Y.C. et al. (2008) Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3.
    Blood. 111: 5054-63.
  5. Litzinger, M.T. et al. (2009) Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients.
    Cancer Immunol Immunother. 58: 955-65.
  6. Sadallah, S. et al. (2011) Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells.
    J Immunol. 186: 6543-52.
  7. Sabbah, S. et al. (2012) T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells.
    Blood. 119 (9): 2083-92.
  8. John, J. et al. (2010) Differential effects of Paclitaxel on dendritic cell function.
    BMC Immunol. 11:14.
  9. Palmer, K.J. et al. (2000) Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC).
    Clin Exp Immunol. 119: 412-8.
  10. Silk, K.M. et al. (2012) Rapamycin conditioning of dendritic cells differentiated from human ES cells promotes a tolerogenic phenotype.
    J Biomed Biotechnol. 2012: 172420.
  11. Elias, F. et al. (2003) Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs.
    J Immunol. 171: 3697-704.
  12. Silk, K.M. et al. (2012) Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells.
    Gene Ther. 19 (10): 1035-40.
  13. del Pilar Martin, M. et al. (2008) Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.
    Arch Neurol. 65: 1596-603.
  14. Keating, S. et al. (2002) The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.
    J Virol. 76: 8179-88.
  15. Trefzer, U. et al. (2000) Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma.
    Int J Cancer. 85 (5): 618-26.
  16. Hayman, M.W. et al. (2006) Soluble human leukocyte antigen: a diagnostic indicator of rheumatoid arthritis?
    J Immunol Methods. 315 (1-2): 19-26.
  17. Manna, D. et al. (2012) WR18 MONOCLONAL ANTIBODY: A SINGLE ANTIBODY TO DETECT HLA DR, DP AND DQ ANTIGENS.
    Abstracts/Human immunology 73:49-167 abstract 36P
  18. Neumann, F. et al. (2004) Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes.
    Cancer Immunol Immunother. 53 (7): 589-99.
  19. Neumann F et al. (2004) Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.
    Int J Cancer. 112 (4): 661-8.
  20. Iking-Konert C et al. (2005) Transdifferentiation of polymorphonuclear neutrophils to dendritic-like cells at the site of inflammation in rheumatoid arthritis: evidence for activation by T cells.
    Ann Rheum Dis. 64 (10): 1436-42.
  21. Hönger, G. et al. (2015) Inter-individual differences in HLA expression can impact the CDC crossmatch.
    Tissue Antigens. 85 (4): 260-6.
  22. del Pilar Martin, M. et al. (2008) Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.
    Arch Neurol. 65 (12): 1596-603.
  23. Noble, P. et al. (2013) High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival.
    Br J Cancer. 108 (10): 2097-105.
  24. Llewelyn, M. et al. (2004) HLA class II polymorphisms determine responses to bacterial superantigens.
    J Immunol. 172 (3): 1719-26.
  25. Koschwanez, H. et al. (2015) Stress-related changes to immune cells in the skin prior to wounding may impair subsequent healing.
    Brain Behav Immun. 50: 47-51.